Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ENOV NASDAQ:IRMD NASDAQ:SLNO NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$21.95-0.1%$23.89$20.55▼$36.82$1.26B1.381.05 million shs1.80 million shsIRMDiRadimed$92.20$90.47$55.11▼$107.90$1.18B0.91136,698 shs182,288 shsSLNOSoleno Therapeutics$53.01$47.81$29.43▼$90.32$2.76B-2.221.75 million shsN/ATMDXTransMedics Group$78.79$83.39$60.10▼$156.00$2.72B1.911.11 million shs1.79 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis0.00%+1.17%-10.77%+0.96%-28.47%IRMDiRadimed0.00%-1.50%-1.04%-7.34%+57.74%SLNOSoleno Therapeutics0.00%0.00%0.00%+59.57%-33.22%TMDXTransMedics Group0.00%+8.06%+14.44%-30.83%-36.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$21.95-0.1%$23.89$20.55▼$36.82$1.26B1.381.05 million shs1.80 million shsIRMDiRadimed$92.20$90.47$55.11▼$107.90$1.18B0.91136,698 shs182,288 shsSLNOSoleno Therapeutics$53.01$47.81$29.43▼$90.32$2.76B-2.221.75 million shsN/ATMDXTransMedics Group$78.79$83.39$60.10▼$156.00$2.72B1.911.11 million shs1.79 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis0.00%+1.17%-10.77%+0.96%-28.47%IRMDiRadimed0.00%-1.50%-1.04%-7.34%+57.74%SLNOSoleno Therapeutics0.00%0.00%0.00%+59.57%-33.22%TMDXTransMedics Group0.00%+8.06%+14.44%-30.83%-36.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENOVEnovis 2.67Moderate Buy$44.50102.72% UpsideIRMDiRadimed 3.00Buy$120.0030.15% UpsideSLNOSoleno Therapeutics 2.08Hold$76.6744.63% UpsideTMDXTransMedics Group 2.46Hold$134.5070.71% UpsideCurrent Analyst Ratings BreakdownLatest IRMD, TMDX, SLNO, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026TMDXTransMedics Group Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$75.00 ➝ $80.006/9/2026TMDXTransMedics Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/1/2026ENOVEnovis Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/26/2026TMDXTransMedics Group UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/26/2026TMDXTransMedics Group Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$85.00 ➝ $75.005/22/2026ENOVEnovis BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.005/20/2026IRMDiRadimed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/19/2026SLNOSoleno Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/11/2026SLNOSoleno Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/8/2026ENOVEnovis EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.005/8/2026ENOVEnovis Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $40.00(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENOVEnovis$2.25B0.56$26.77 per share0.82$26.09 per share0.84IRMDiRadimed$83.81M14.06$1.86 per share49.60$7.44 per share12.39SLNOSoleno Therapeutics$285.01M9.69$0.43 per share124.10$9.51 per share5.57TMDXTransMedics Group$605.49M4.50$3.93 per share20.06$13.79 per share5.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENOVEnovis-$1.18B-$19.88N/A5.52N/A-49.92%10.32%4.57%8/6/2026 (Estimated)IRMDiRadimed$22.48M$1.8350.38N/AN/A27.36%24.48%21.25%7/30/2026 (Estimated)SLNOSoleno Therapeutics$20.89M$1.7729.959.89N/A33.70%22.85%18.25%8/5/2026 (Estimated)TMDXTransMedics Group$190.29M$4.4017.9121.83N/A27.04%22.38%8.46%7/30/2026 (Estimated)Latest IRMD, TMDX, SLNO, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ENOVEnovis$0.82$0.89+$0.07-$0.15$572.02 million$589.15 million5/5/2026Q1 2026TMDXTransMedics Group$0.62$0.30-$0.32$0.20$174.44 million$173.93 million5/1/2026Q1 2026IRMDiRadimed$0.46$0.49+$0.03$0.45$21.32 million$21.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENOVEnovisN/AN/AN/AN/AN/AIRMDiRadimed$0.800.87%N/A43.72%1 YearsSLNOSoleno TherapeuticsN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ALatest IRMD, TMDX, SLNO, and ENOV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026IRMDiRadimedquarterly$0.200.93%5/15/20265/15/20265/29/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENOVEnovis0.872.041.05IRMDiRadimedN/A7.136.15SLNOSoleno Therapeutics0.105.625.32TMDXTransMedics Group1.706.746.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENOVEnovis98.45%IRMDiRadimed92.34%SLNOSoleno Therapeutics97.42%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipENOVEnovis2.90%IRMDiRadimed34.60%SLNOSoleno Therapeutics6.40%TMDXTransMedics Group6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENOVEnovis7,80257.56 million55.89 millionOptionableIRMDiRadimed11012.78 million8.36 millionOptionableSLNOSoleno Therapeutics3052.12 million48.78 millionOptionableTMDXTransMedics Group21034.56 million32.18 millionOptionableIRMD, TMDX, SLNO, and ENOV HeadlinesRecent News About These CompaniesVirtu Financial LLC Buys 22,202 Shares of TransMedics Group, Inc. $TMDXJune 19 at 6:47 AM | marketbeat.comTransMedics Group (NASDAQ:TMDX) Price Target Raised to $80.00June 18 at 8:46 AM | marketbeat.comInsider Selling: TransMedics Group (NASDAQ:TMDX) Director Sells 9,624 Shares of StockJune 18 at 7:55 AM | insidertrades.comJohnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP InvestmentsJune 12, 2026 | globenewswire.comTransMedics Group Inc.June 11, 2026 | barrons.comTransMedics: Why I'm Still Bullish After The CollapseJune 9, 2026 | seekingalpha.comAnalysts Are Bullish on Top Healthcare Stocks: Charles River Labs (CRL), TransMedics Group (TMDX)June 6, 2026 | theglobeandmail.comWill Analyst Focus on TransMedics’ OCS Platform and Financial Metrics Change TransMedics Group’s (TMDX) Narrative?June 6, 2026 | uk.finance.yahoo.comTransMedics Group, Inc. (TMDX) Presents at 46th Annual William Blair Growth Stock Conference - SlideshowJune 4, 2026 | seekingalpha.comTransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?June 4, 2026 | zacks.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Hold" by BrokeragesJune 2, 2026 | marketbeat.comReasons to Retain TransMedics Stock in Your Portfolio for NowMay 28, 2026 | zacks.comStifel Nicolaus Lowers TransMedics Group (NASDAQ:TMDX) Price Target to $75.00May 26, 2026 | marketbeat.comTransMedics: Despite Earnings Miss, Growth Story Remains IntactMay 25, 2026 | seekingalpha.comTransMedics Shareholders Reelect Board and Approve Executive PayMay 21, 2026 | tipranks.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 21, 2026 | prnewswire.comTransMedics Group Signals Growth Amid Margin SqueezeMay 21, 2026 | theglobeandmail.comTransMedics Group (NASDAQ:TMDX) Gains Momentum In Healthcare SpaceMay 19, 2026 | kalkinemedia.comKTransMedics to Present at the William Blair 46th Annual Growth Stock ConferenceMay 19, 2026 | prnewswire.comTransMedics Group (TMDX) price target decreased by 22.22% to 126.07May 14, 2026 | msn.comAssessing TransMedics Group (TMDX) Valuation After A Sharp One Year Share Price DeclineMay 11, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRMD, TMDX, SLNO, and ENOV Company DescriptionsEnovis NYSE:ENOV$21.95 -0.02 (-0.08%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$21.73 -0.22 (-1.00%) As of 06/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.iRadimed NASDAQ:IRMD$92.20 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$92.70 +0.50 (+0.55%) As of 06/18/2026 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Soleno Therapeutics NASDAQ:SLNOSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.TransMedics Group NASDAQ:TMDX$78.79 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$78.88 +0.09 (+0.11%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
